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Abstract
Many industrialized countries have implemented routine immunization policies for older adults, 
but similar strategies have not been widely implemented in low- and middle-income countries 
(LMICs). In March 2017, the World Health Organization (WHO) convened a meeting to identify 
policies and activities to promote access to vaccination of older adults, specifically in LMICs. 
Participants included academic and industry researchers, funders, civil society organizations, 
implementers of global health interventions, and stakeholders from developing countries with 
adult immunization needs. These experts reviewed vaccine performance in older adults, the 
anticipated impact of adult vaccination programs, and the challenges and opportunities of building 
or strengthening an adult and older adult immunization platforms. Key conclusions of the meeting 
were that there is a need for discussion of new opportunities for vaccination of all adults as well as 
for vaccination of older adults, as reflected in the recent shift by WHO to a life-course approach to 
immunization; that immunization in adults should be viewed in the context of a much broader 
model based on an individual’s abilities rather than chronological age; and that immunization 
beyond infancy is a global priority that can be successfully integrated with other interventions to 
promote healthy ageing. As WHO is looking ahead to a global Decade of Healthy Ageing starting 
in 2020, it will seek to define a roadmap for interdisciplinary collaborations to integrate 
immunization with improving access to preventive and other healthcare interventions for adults 
worldwide.
Keywords
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development
1. Introduction
Vaccination of older adults has been shown to reduce transmission and serious disease 
caused by vaccine-preventable diseases mainly in high income countries (HIC), but the 
policy of vaccinating this age group has not been widely implemented in LMICs. The World 
Health Organization (WHO) convened a meeting in March 2017 to review policies on 
immunization of adults (with a focus on older adults), to discuss vaccine performance in this 
group and to review the pipeline of vaccines under development that might be of benefit to 
adults and older adults in the future. While the meeting was relevant to HICs as well as 
LMICs, the focus was intentionally on the latter. The only vaccines with WHO 
recommendations for specific use in elderly adults are influenza vaccines [1], therefore 
influenza and influenza prevention represented an important case study and area of 
discussion in the meeting for vaccine policy and implementation needs globally. Finally, the 
meeting aimed to discuss the challenges and opportunities for strengthening adult 
immunization in LMICs and to identify activities and policies that can be pursued to this 
end.
This was the first WHO meeting on older adult immunization since 2011 [2]. The objectives 
of the meeting were the following: (1) to review policies on immunization of adults, with a 
focus on older adults; (2) to discuss the incidence and determinants of vaccine preventable 
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diseases in adults; (3) to discuss vaccine performance in older adults and the pipeline of 
vaccines under development that may be of benefit to adults and older adults; (4) to discuss 
challenges and opportunities for strengthening an adult immunization platform in low- and 
middle-income countries; and (5) to identify policies that could be developed and activities 
that can be pursued to promote access to vaccination for older adults in LMICs. Participants 
included academic and industry researchers, funders, civil society organizations, 
implementers of global health interventions, and stakeholders from developing countries 
with adult immunization needs. The agenda and list of participants are in the Online 
Supplement. The two-day meeting was organized around a series of background topic areas, 
followed by case studies in LMICs, and then discussion on data needs for policies and 
investments of vaccine programs targeting older adults. This report is based on presentations 
and discussion from the meeting.
2. Ageing and vaccination
2.1. Changing demographics and markets for vaccines
The world population is ageing. The number of individuals aged 60 and older is predicted to 
increase from 600 million to 2 billion from 2000 to 2050, with 80% of older adults living in 
developing regions [3], with a preponderance of women [4]. As people age, they develop 
increased susceptibility to many infectious diseases. As part of a broad public heath strategy 
the number of vaccine doses needed to target older adults is anticipated to outpace those 
needed by routine pediatric immunization programs.
Some countries are developing plans for this demographic change, but many countries do 
not have vaccination policies specifically targeting adult populations. Even in HICs, 
vaccination use in adults can be low [5]; for example, despite a WHO recommendation, only 
45% of 115 member states with an influenza policy include programs targeting the “elderly” 
risk group, and most of these are HICs [6].
For the purposes of this report, older adults are defined as people in the second half of their 
life, i.e. over half of the life expectancy for a particular country. While examples and 
discussion specific to older adults are provided in this report, sometimes when the data 
specific to older adults are sparse or when discussion of a broader age group is warranted, 
the report refers to all adults.
2.2. WHO vaccine recommendations and age
Current WHO guidance on routine vaccines, summarized in WHO vaccine position papers 
[7], focuses heavily on pediatric immunization. There is some consideration of 
immunization in pregnancy, immunization in health-care workers, high-risk occupations, 
notes on travel vaccines or regional use, but few recommendations for vaccination to protect 
adults in general against infectious diseases, with the exception of a permissive 
recommendation for influenza vaccine use in elderly persons and persons with chronic 
disease. The older target group is not defined by WHO, and countries have implemented 
“elderly” influenza vaccine programs beginning at a variety of ages (including 50, 60, and 
65 years).
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WHO has a mandate within the Global Vaccine Action Plan 2011–2020 to “improve health 
by extending by 2020 and beyond the full benefits of immunization to all people, regardless 
of where they are born, who they are, or where they live” [8]. Furthermore, the WHO 
Initiative for Vaccine Research (IVR) has long been interested in immunization of older 
adults, and has held and contributed to relevant meetings on the topic over the past decade 
[2], which have influenced the research agenda worldwide. Of the major data gaps 
previously identified, most still remain [2]. These include disease burden data for many 
vaccine preventable diseases in older adults, duration of protection of routine childhood 
vaccines among older adults, performance of new vaccines targeting older adults within 
LMIC contexts, and how to identify the optimal time for immunization of older adults to 
ensure sufficient immunologic response and memory.
One goal in the WHO’s Global Strategy and Action Plan on Ageing and Health [9] is to 
design interventions to prevent disease and to influence trajectories of individuals’ intrinsic 
capacity (defined as a combination of one’s physical and mental capacities). One of the 
important activities to promote healthy ageing is to “ensure access and affordability of 
medical products, vaccines, and technologies” as part of integrated care for people in the 
second half of life [10].
2.3. Definitions: at what age are people considered old?
Healthy ageing is defined by the WHO as “the process of developing and maintaining the 
functional ability that enables wellbeing in older age” [11]. This ability depends on both an 
individual’s physical and mental capacities and on the environments one inhabits (for 
example access to transport and assistive devices) [10]. As described in the WHO’s World 
Report on Ageing and Health [11], while intrinsic capacity tends to decline with increasing 
age, a primary characteristic of older ages is great diversity. Even in the poorest settings, an 
eighty year old may be healthy, independent, and vibrant, while a sixty year old may need 
significant care and support. Chronological age is thus a poor marker of health state, and 
there is no fixed age when someone becomes “old”. Furthermore, this diversity is often a 
consequence of the cumulative impacts of advantage or disadvantage across a person’s life. 
This means that those with the greatest health needs in older age may have the least access 
to the specific required resources.
In any population in the second half of life, three groups can be proposed: those with high 
and stable capacity; those with decreasing capacity; and those with substantial loss of 
capacity [10], although individuals can transition between these states. Rather than defining 
target groups for vaccination solely by their chronological age, assessing an individual’s 
level of capacity may add important information on their need for vaccination, response to 
vaccination, or the functional benefits likely to arise. For example, where a vaccine is 
currently recommended for those above 65 years [12], some individuals may benefit from 
vaccination at an earlier age because of declining capacity. While implementing this 
approach would require development and adoption of simple and robust measures of 
capacity in a clinical setting, discussions of this topic may be beneficial in order to better 
understand optimal target groups for vaccination.
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3. Reasons for vaccination of adults and older adults
Discussion in the meeting highlighted many reasons and benefits for vaccinating older adults 
and, indeed, any age group after infancy (see Table 1).
3.1. Examples of benefits of vaccinating older adults
Respiratory pathogens, such as Haemophilus influenzae type b (Hib), influenza virus, 
respiratory syncytial virus (RSV) [13] and Streptococcus pneumoniae [14–16] are key 
targets for vaccine development and implementation in older adults in HICs, and vaccination 
of adults or older adults should have an impact on the burden of these diseases in LMICs.
When studied from 2005 to 2008, influenza activity in Thailand correlated with hospital 
admissions and deaths in older adults. This finding led to a policy of administering 
domestically-manufactured influenza vaccines to high-risk older adults [17,18]. Similar 
studies have been conducted in Central America [19], Ghana [20], and India [21], 
demonstrating the burden of disease in older adults and the unrealized potential impact of 
vaccine programs targeting them. There are more limited data on other respiratory infections 
in older adults; for example, two Thai studies [16,22] found many hospitalized 
Streptococcus pneumoniae cases were in older adults and authors called for cost 
effectiveness data to inform future vaccine use.
In some cases, childhood vaccination can affect disease in older adults due to population 
(herd) immunity, providing sufficient vaccine effectiveness (VE) and coverage can be 
achieved. This has been observed with influenza vaccination in Japan [23] and the United 
States [24]. In some settings, it has been suggested that a highly effective infant influenza 
vaccination program might make vaccinating older adults unnecessary [25], but further data 
are necessary. Another vaccine example is the a substantial positive impact of pneumococcal 
vaccination of infants and children on mortality and morbidity of seniors which was 
observed in the United States [26].
Another benefit of vaccinating people of all ages is an indirect effect on the ability of 
microbes to resist the effects of drugs, or anti-microbial resistance (AMR). The Global 
Action Plan on AMR [27] states that immunization could reduce AMR in three ways: first, 
by using existing vaccines to prevent infectious diseases whose treatment would require 
antimicrobials; second, by using existing vaccines to reduce the prevalence of primary viral 
infections which are often inappropriately treated with antibiotics or that can lead to 
secondary infections that require antibiotic treatment [28]; and, third, by the development 
and use of new vaccines targeting pathogens difficult to treat (or untreatable) due to AMR. 
In addition, vaccination might selectively target resistant strains of an organism, reduce the 
opportunity for pathogens to exchange resistance genes, or reduce bystander selection of 
resistance in normal flora species [29].
Several studies illustrate how existing vaccines can reduce infections in vaccinees of all ages 
[30] and through population (herd) immunity [31], but very few studies have been conducted 
to measure vaccine effectiveness at preventing anti-microbial use or AMR. As secondary 
outcomes of pneumococcal conjugate vaccine (PCV) use, some studies in infants in HICs 
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have shown a reduction in antibiotic prescription [32], a reduction in antimicrobial purchases 
[33], or reduced duration of antibiotic use [34]. Modeling studies have concluded that high 
coverage with PCV in 75 countries not currently achieving 80% coverage could avert many 
millions of days of antibiotic use in young children [35].
Low-income countries (LICs) are at highest risk of AMR [36], so vaccine use in those 
countries could potentially yield the greatest benefits. There is, however, a significant lack of 
data on the impact of vaccines on AMR in LICs, especially in older adults.
3.2. Health economics of vaccination of adults and older adults
Health economic evaluations such as cost-effectiveness analysis are important tools for 
investigating whether the social and economic benefits of an intervention such as 
vaccination outweigh the opportunity costs of the intervention. However, evaluations of 
vaccination of adults and older adults in LMICs are severely lacking compared to similar 
evaluations of pediatric vaccination. For example, two reviews of cost-effectiveness studies 
of seasonal influenza vaccination found only five studies for older adults in LMICs [37,38].
Many economic evaluations do not capture some of the broader economic benefits of 
vaccination at the individual, household and society level that are particularly relevant to 
adult vaccination. For example, evaluations of the indirect benefits of vaccination should 
consider the roles older adults play in the volunteer sector and as caregivers in families and 
communities, looking after infants and children as part of the “informal economy” [39]. 
These aspects may be particularly valuable in LMICs [40]. In addition, traditional measures 
of health utility such as quality- or disability-adjusted life years may not capture what older 
adults value most about good health and maintenance of functional ability. Alternative 
measures of health utility for older adults have been proposed, including independence, and 
ability to do the things that they value [41].
The impact of population (herd) immunity adds a further level of complexity to economic 
evaluations. In some settings, it might be more cost-effective to protect older adults from an 
infection by vaccinating infants to eliminate the infant reservoir of the pathogen. Consensus 
guidelines for methodological approaches to estimating direct and indirect costs of vaccine-
preventable diseases in LMICs are required, and are being developed by WHO for influenza 
[42]. Similar guidance would be of value for other vaccine preventable diseases that 
disproportionately affect older adults.
4. Protection of older adults
4.1. Vaccine performance in older adults
Vaccine performance can be measured by vaccine immunogenicity, efficacy, or 
effectiveness. Vaccines can be less immunogenic in older adults due to immunosenescence 
(see Section 4.2). Concomitant anti-inflammatory and immunomodulatory therapies are 
more likely to have significant negative interactions with vaccines in older adults [43]. 
Immune responses (and adverse reactions) to vaccines tend to be higher in females than 
males, and loss of function with age might be more frequent or of greater magnitude in 
males [4]. At all ages, vaccine effectiveness tends to be higher in women than in men [4].
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Often vaccines have a lower vaccine effectiveness in older adults compared to younger 
adults, and several approaches have been used to overcome this: (a) increasing the number of 
doses administered, (b) increasing the dose of antigen in the formulation, and (c) 
incorporating adjuvants, such as MF59 in the Fluad® seasonal influenza vaccine [44]. It has 
been proposed that early-season use of influenza vaccines might result in antibodies that 
wane by the start of a late-season virus circulation [45] so the timing of vaccination could 
also be important.
The performance of seasonal influenza vaccines in older adults has been reviewed in several 
meta-analyses [46,47], and vaccine effectiveness has been observed to be suboptimal 
compared to other age groups. However, recent systematic reviews of the use of adjuvanted 
influenza vaccine formulations [44] and intradermal administration [47] have shown 
improved immunogenicity of seasonal influenza vaccines in the elderly. These studies have 
been conducted in HICs and less data are available on influenza vaccine use in adults in 
LMICs [48]. PCV and pneumococcal polysaccharide vaccine (PPV) effectiveness have also 
been reviewed; PPV effectiveness was found to be 50% [30] and PCV effectiveness was 
48.5% in preventing invasive pneumococcal disease in healthy adults aged 65 years and over 
[49].
Analyses have shown that the high-dose influenza vaccine in older adults (Fluzone®, Sanofi 
Pasteur) performs better in older adults than the standard influenza vaccines [50]. It has a 
higher VE, and induces higher antibody responses in adults aged more than 65 years 
compared with the standard formulation (60 µg HA vs 15 µg HA per dose). A 
supplementary analysis showed the high-dose vaccine was better at preventing serious 
cardio-respiratory events and pneumonia than the standard vaccine [51], and a retrospective 
cohort study in the United States found the vaccine to be more effective than the standard 
dose vaccine in preventing influenza-related medical encounters, hospital admissions, and 
death in adults 65 years of age and older [52–54].
4.2. Immunosenescence and biomarkers
Studies of immunosenescence in preclinical models and humans have identified many 
aspects of adaptive and innate immune responses that decline or change with age [55]. 
Biomarkers for these changes have the potential to inform more rapid vaccine development 
for older adults. The number of naïve T lymphocytes declines with age, following involution 
of the thymus after puberty, compromising the ability to respond to new vaccinations (or 
infections). It has also been suggested that the expanded T cell responses required to keep 
persistent infections controlled, such as Epstein Barr virus and human cytomegalovirus 
(HCMV), reduces “space” for new T cells, particularly CD8+ T cells [55]; however, the 
effect of HCMV infection on immune function, including the response to influenza vaccine, 
appears to be heterogeneous, and is seen only in older individuals who might have had 
persistent HCMV infection for decades [56]. Recently, older adults were shown to have 
increased senescent and exhausted varicella zoster virus (VZV)-specific T cells which may 
contribute to their inability to prevent VZV reactivation and the subsequent development of 
herpes zoster [57].
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The number and function of B lymphocytes also decreases with age, with an increase in the 
number of late/exhausted B cells that are terminally differentiated, non-proliferating and 
with poor effector function [58,59]. Many immune cell types express a senescence-
associated secretory phenotype, defined as the secretion of several pro-inflammatory 
cytokines including tumor necrosis factor alpha, interleukin 6 and interleukin 8 [55,58], 
which promotes chronic low-grade inflammation. Numbers of dendritic cells (DCs) and 
Langerhans cells decline [60], and DCs exhibit reduced phagocytosis and class 1 human 
leucocyte antigen expression [55].
These changes in immune function have been shown to impair primary responses to yellow 
fever (YF) vaccine in travelers, even though protective levels were still achieved [60]. 
Memory immune responses, such as to seasonal influenza vaccine, have also been shown to 
be affected [58].
Despite immunosenescence, it is still possible to induce immune responses in older adults 
that are protective or equivalent to those seen in younger age groups; examples include: (a) 
phase III trials of the two-dose HZ/Su subunit vaccine branded as “Shingrix” against herpes 
zoster that showed similar vaccine efficacy in ages 50 years and older [61] and 70 years and 
older (~90%) [62]; (b) phase I/II trial of a candidate Staphylococcus aureus single dose, non-
adjuvanted, inactivated vaccine in healthy adults aged 65 –85 years showed that functional 
antibody responses which met pre-defined thresholds in the older adults [63]; and (c) two 
trials with different Clostridium difficile vaccines that showed similar responses across 
different age groups [64,65].
Identification of biomarkers of immunosenescence might inform rational design of vaccines, 
for example those that include novel adjuvants, to enhance immune responses in older 
adults, or could be used to identify individuals who are unlikely to respond to a given 
vaccine. Systems approaches in biology research are being used to identify such markers 
[66]. Data obtained to date suggest that the changes observed in immunosenescence are also 
found in many fundamental biological pathways such as cell proliferation and hormone 
regulation as well as lymphocyte activation and differentiation [66].
Although most of the data on ageing and immunosenescence have been collected in HICs, a 
pilot study conducted in Pakistan found similar changes in immune cell phenotypes in young 
(aged 18–28 years) and older (aged 50–85 years) men, to those seen in HICs [67].
5. Vaccines that are or could be of benefit to older adults
Multiple licensed vaccines are currently used in adults, although they remain underused in 
the general adult population and in some target groups. In addition, there are new vaccines 
for adults in the development pipelines of many vaccine manufacturers (Table 2).
Some of the vaccines in Table 2 are of interest for people of any age with low intrinsic 
capacity, such as Staphylococcus aureus [68]; extraintestinal pathogenic Escherichia coli, 
because of its role in urinary tract infections [69]; and C. difficile, because of its high 
morbidity and mortality, especially in older adults. These three pathogens are also important 
targets from the perspective of reducing AMR.
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6. Considerations for vaccination of adults and older adults in LMICs
As stated above, much of the data on the need for, and use of, vaccines for adults comes 
from studies in HICs. There are, however, important differences between HIC and LMICs 
that need to be taken into consideration, including specifics related to adult immunization in 
terms of disease epidemiology, health infrastructure, opportunities for life-course 
immunization, and policymaking in this age group.
6.1. Disease epidemiology and comorbidities
The epidemiology and timing of infectious diseases can be very different in LMICs, based 
on factors such as differential exposure due to climate, geography and hygiene and an earlier 
risk of exposure to a diverse and larger number of pathogens. In addition, co-infections such 
as tuberculosis or human immunodeficiency virus (HIV) can affect the risk of severe 
outcomes from vaccine preventable diseases as well as the immune response to vaccines 
[70]. Immune responsiveness can also be affected by differences in nutrition, such as 
vitamin A deficiency [71], and obesity [72]. There is also evidence, albeit in infants, that 
diet, exposure to microorganisms and parasites, and anti-microbial (and anti-helminthic) use 
can affect the immune system [73]. In general, there may be a myriad of environmental 
conditions that result in a different picture of co-morbidities of infectious diseases and other 
non-communicable diseases (NCDs) and conditions in LMICs compared with HICs. 
Reduced access to healthcare and social services in LMICs can also affect an individual’s 
functional capacity at any age, and can limit access to vaccination.
6.2. Health infrastructure for adult vaccination
The implementation in 1974 of the Expanded Programme on Immunization (EPI) has meant 
that routine immunization infrastructure has focused on neonates, infants (e.g. immunization 
visits at ages 6, 10 and 14 weeks, and 9 months) and pregnant women. Achieving high 
vaccination coverage in target groups outside the traditional program can be difficult. 
Countries considering strengthening immunization platforms for older adults would benefit 
from strategies and lessons learned from similar efforts in other age groups [74]. Currently, 
more than 80 countries have introduced human papillomavirus (HPV) vaccine into their 
national immunization programs, usually with school-based vaccination; 33 of these are 
LMICs, and an additional 25 LMICs are undertaking pilot programs prior to full scale 
introduction [75]. Lessons learned from HPV programs [76], including the usefulness of 
pilots or demonstration projects [77], could be valuable for establishing new platforms for 
adult vaccines, especially ones where multi-dose regimens are required [78]. For example, 
adults taking infants to a pediatric vaccination clinic could also be offered immunizations or 
other services.
6.3. Opportunities within life-course immunization in LMICs
A major barrier in many LMICs is that there is often not a comprehensive health system to 
reach all adults, including older adults, for preventive healthcare. If one could be established, 
it could have many benefits for all kinds of health interventions, including screening, 
diagnostics and treatments.
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There is interest within the vaccine community, and those whose primary focus is the health 
of older adults in general, on new opportunities to build preventive and other healthcare 
services around or including immunization. Life-course immunization may include the 
following healthcare points and systems: well-baby, school-entry, school-leaving, general 
practice, community pharmacies [79], community nurses, adolescent health, universities and 
colleges, ante-natal care, outpatient clinics for the chronically sick, nursing homes, military 
services, services for new migrants, and travel vaccination clinics.
Many healthcare systems may benefit from increasing attention on disease prevention, 
particularly in LMICs. Increasingly, there is anticipated to be a shift to self-management of 
and prevention of medical conditions, with individuals taking more responsibility for their 
health, which could include demanding vaccines for themselves or their parents or other 
family members.
6.4. Mandates and policymaking
Although adults and older adults are not often explicitly identified as target groups for 
vaccination, they are included in global strategies and policies. The stated vision of the 
Decade of Vaccines (2011–2020) is for “a world in which all individuals and communities 
enjoy lives free from vaccine-preventable disease” [8]. In addition, Goal 3 of the United 
Nations Sustainable Development Goals [80] is to “ensure healthy lives and promote well-
being for all at all ages”, and includes a target of “access to safe, effective, quality and 
affordable essential medicines and vaccines for all”.
Despite broad, bold policy statements, however, there is often delayed uptake of new 
vaccines for some target groups and ages for a variety of reasons [81], some of which are 
especially applicable to adult vaccination. For example, successful introduction of any new 
vaccine requires engagement and alignment of multiple stakeholders. Governments must see 
the value in a new vaccine before they are willing to introduce it and this requires 
recognition of the burden of disease and the fact that an affordable, deliverable vaccine is 
available. Purchasers (donors, governments or private health providers) are unlikely to pay 
for the vaccine unless they think it will be seen as a priority by end users, and vaccine 
developers and manufacturers will not produce the vaccine unless they believe it will be 
purchased. Other reasons relate to the general lack of awareness by adults that vaccine-
preventable diseases such as pneumococcal pneumonia, influenza and shingles can have 
devastating effects on the health, function and socioeconomic contributions of a normal 
healthy older person, let alone those who may have a chronic condition such as diabetes.
To promote influenza vaccination of older adults, for example, it might be important to 
recognize that seasonal influenza infections do not just result in a short-term increase in 
accelerated mortality, but also result in low-quality of life and morbidity that can extend for 
several months after the influenza season [82]. The costs of the social and economic burden 
need to be quantified for the stakeholders in question. In some situations, to stimulate uptake 
of vaccines for an ageing population, it might be preferable to re-frame the narrative to one 
that reflects the contributions that older adults across society make with advancing age in 
good health or simply their higher quality of life.
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7. Barriers to adult vaccination
Adult vaccine coverage is low, even in HICs, for a variety of reasons [83]. Perceived and 
actual barriers can be categorized at the level of the individual and community demand for 
vaccines, or with the vaccination process and system (Table 3). This list of barriers has been 
modified from a prior publication [79], with additional information based on presentations 
and discussion at the meeting. Some of the barriers apply to vaccination of all age groups; 
others are specific or more relevant to vaccination of adults.
Despite the barriers to vaccination after infancy, some which are listed in Table 3, many 
countries are gaining experiences that should be useful in the future and to other countries 
[84]. The International Federation on Ageing’s World Coalition on Adult Vaccination [85] is 
one of several global and regional projects aiming to help improve uptake rates of adult 
vaccination through building an understanding of the community and systemic barriers and 
then working across sectors and disciplines to create solutions.
8. Gaps in knowledge
One of the objectives of the meeting was to identify challenges and opportunities for 
strengthening adult immunization in LMICs. Significant gaps in knowledge regarding 
vaccination of adults and older adults, particularly in LMICs, were identified (Table 4). Most 
of the existing data that are available come from HICs, or a limited number of MICs (Brazil, 
China, India, Mexico, Thailand). Some MICs have parts of their population with some 
characteristics of HIC and other parts that are under-developed. They could represent good 
settings to compare interventions in different subpopulations of the same country exposed to 
different conditions.
9. Conclusions
There are global mandates to expand and strengthen immunization in older adults, however 
critical data to inform policy making and public health practice in LMICs remain limited. 
More data are needed on vaccine-preventable disease burden in older adults in LMICs and 
the estimated impact vaccines would have on this burden. Further, new ways to look at 
impact of vaccine programs, that take into account the contributions of healthy older adults 
and the consequences of their declining intrinsic capacities to society, are needed. Two clear 
conclusions from the meeting were that immunization of adults should be viewed as a key 
component of a comprehensive approach to health, and that protecting older adults from 
vaccine-preventable diseases might mean achieving high vaccine coverage in all age groups 
(including infants), and not simply older adults. Additionally, the need for vaccine research 
and development related to immunosenescence was identified, given the remarkable increase 
in the population of older adults.
To achieve significant increases in adult vaccination coverage, the knowledge gaps listed in 
Table 4 should be addressed. Equally important will be the need for a shift in overall 
thinking about providing protection against vaccine-preventable diseases, which has to date 
focused nearly exclusively on vaccination of infants [86]. Activities to improve coverage 
with infant vaccines should not diminish, but an increasing emphasis needs to be placed on 
Aguado et al. Page 11
Vaccine. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
life-course approach to immunization schedules to protect adults and older adults, especially 
given the significant and changing demographics of the global population. There is already 
some evidence from HICs of the benefits of using existing vaccines in older adults [49,82]. 
Although the efficacy of some vaccines might be lower in older adults than is usually seen 
with infant vaccines, these data need to be viewed in the context of the increased risks from 
disease and broader social and economic benefits of prevention in older populations. 
Misconceptions about the benefits of vaccination of older adults should not prevent its use.
Decreasing adult preventable disease through improved uptake of appropriate vaccines will 
require strong champions, both individual and institutional [87], at a time when there are 
many competing priorities for health spending. Obtaining data is critical to gaining a deeper 
understanding of the impact of adult vaccination on problems such as AMR, as well as the 
growing need to guard against preventable illnesses in an ageing global population with co-
morbidities and concomitant conditions. The “business case,” that is, the direct and indirect 
associated health-care and broader societal costs and benefits, is critical to justify a life-
course approach to vaccination. Raising awareness of the importance of vaccination of 
adults and older adults is just the beginning of truly cementing the intervention within a 
broader public health strategy.
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Table 1
Reasons for vaccinating after infancy.
Reason Notes and examples
Improving population (herd) immunity and disease control
Catch-up - coverage with the complete schedule of infant 
vaccines is not 100%, leaving some of the population 
unprotected
Global burden of disease data for tetanus mortality, showing that most cases are 
in LMICs and deaths are at all ages [88]
The vaccine(s) in question might not have been in use while 
the adult population were infants
Applies to recent vaccine introductions, such as measles, mumps and rubella 
(MMR), hepatitis B virus, varicella zoster virus, and pneumococcal conjugate 
vaccine
Protection against pathogens with changing strains or 
serotype prevalence that might differ in different age groups
Examples include: influenza and Streptococcus pneumoniae (pneumococcus)
Protecting at-risk populations after childhood
Protection against occupation-associated exposure to 
specific pathogens
Especially healthcare workers, food handlers, laboratory workers, but also those 
with close contact with animals
Prevention of infections in hospitalized patients Examples include: Methicillin-resistant Staphylococcus aureus; C. difficile; 
norovirus
Respiratory diseases can have serious impacts in adults/
older adults. Higher rates of morbidity or mortality with 
older onset of other infections
There is a link between seasonal influenza and functional decline in activities of 
daily living in people living in nursing homes in the USA, [89]. Varicella case 
fatality rate in older adults is 25–174-fold higher, compared with children [55]
Risk of infection increases, or has higher morbidity, with 
chronic conditions
An example includes, Hepatitis B and diabetes due to cross-infection in 
healthcare settings [90]
Protection through the life-course
Vaccination of women before or during pregnancy to 
protect themselves and their infants
Examples include: diphtheria, influenza, pertussis, polio, MMR, varicella, 
tetanus [91]
Vaccination to prevent unnecessary antibiotic use given the 
growing concerns about antimicrobial resistance
The following pathogens have developed significant drug-resistance: 
Acinetobacter baumannii, candida sp., C. difficile, diphtheria, Enterobacter sp., 
Enterococcus faecium, Escherichia coli, gonococcus, Haemophilus influenzae 
type B, HIV, Klebsiella pneumoniae, malaria, meningococcus, Mycobacterium 
tuberculosis, Pseudomonas aeruginosa, typhoidal and non-typhoidal Salmonella, 
Shigella sp., Staphylococcus aureus, tetanus
Vaccination of travelers Examples include: hepatitis A virus, polio, typhoid, yellow fever, and others
Prevention of chronic and latent infections Examples include: Mycobacterium tuberculosis, herpes simplex virus, varicella 
zoster virus, hepatitis B virus [92]
Secondary prevention of non-communicable diseases 
(NCDs)
Some infections are being linked to causality of NCDs. Influenza vaccination 
could reduce cardiovascular events in at-risk people, including the middle aged 
[93,94]. Influenza vaccine reduced major cause-specific mortality (stroke, renal 
disease, diabetes, pneumonia, chronic-obstructive pulmonary disease, 
malignancy and heart disease) in Taiwanese older adults [95]
Deterioration of the immune system with age could 
compromise the homeostatic equilibrium between 
microbiota and host
Reduced bacterial diversity in the gastrointestinal tract is correlated with C. 
difficile-associated diarrhea [55]
Vaccines needed for protection against emerging diseases, 
outbreaks and pandemics
Examples include chikungunya, cholera, Ebola, Middle East respiratory 
syndrome, severe acute respiratory syndrome, pandemic influenza, tick-borne 
encephalitis and Zika
Note: Gathered from presentations and discussion at the WHO meeting.
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Table 2
Examples of licensed vaccines, or vaccines in development, for use in adults– by stage of development, as of 
2017.
Stage Vaccines
Preclinical Influenza, Respiratory syncytial virus
Phase I Clostridium difficile, HIV, Respiratory syncytial virus
Phase II Ebola, Enterotoxigenic Escherichia coli, Extra-intestinal pathogenic Escherichia coli, HIV, Norovirus, Respiratory 
syncytial virus, Staphylococcus aureus, Streptococcus pneumoniae (pneumococcus),
Phase III Clostridium difficile, Varicella zoster virus
Licensed Diphtheria tetanus pertussis, Hepatitis A virus, Hepatitis B virus, influenza, meningococcal meningitis, pneumococcus, 
Varicella zoster virus, Haemophilus influenzae type b
Not publicly known Group B streptococcus, Zika virus
Notes: Vaccines exclusively for maternal immunization to protect newborns and cancer immunotherapies have not been included. Vaccines for 
pathogens in bold were discussed at the WHO Product Development for Vaccines Advisory Committee 2016 meeting; references are on the 
meeting website [96] See also the WHO Vaccine Pipeline Tracker [97] for references for dengue, Ebola, enteric diseases, HIV, malaria, 
Mycobacterium tuberculosis, Respiratory syncytial virus, Zika virus and other priority emerging pathogen and WHO information on vaccines and 
diseases for landscape analyses [98].
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Table 3
Barriers to vaccination – including barriers specific to adult vaccination, WHO meeting on immunization in 
older adults, March 2017.
Category Barrier Response
Evidence for action Lack of burden of disease and economic data and/or policy recommendations; 
weak value proposition
Generate burden of disease 
data, evidence of VE; strong 
statement(s) from trusted 
source (e.g. WHO); promote 
evidence to national 
immunization technical 
advisory groups (NITAGs) and 
medical associations
Individual factors and 
information
Vaccine hesitancy or lack of awareness and action due to insufficient information, 
knowledge, skill, or time; or too-complex information
Improve communication 
methods, inform and motivate 
communities. Increase access 
to vaccine information, 
preferably with tailored 
information
Vaccination process Adult vaccine schedules (or information) can be highly complex. Pathways to 
access vaccination can be complex, vaccinees might need to make several visits 
to get prescription, supplies and then vaccination itself.
Simplify schedules or explain 
better. Integrate vaccination 
history with electronic medical 
records. Simplify and bring 
services closer to where adults 
live, work, study or currently 
seek medical care (e.g. ante-
natal clinics). Self-
administration of vaccines 
could overcome some 
immunization logistics 
obstacles
Infant programs are often prioritized by communities and governments
Vaccination system Limitations in vaccination infrastructure are widespread and include:
• Lack of advice for National Immunization Technical Advisory 
Groups from experts in adult vaccination
• Lack of public sector support for adult vaccines and limited 
promotion of adult vaccination
• Limited resources to purchase and deliver adult vaccines. In many 
countries adults ‘‘self-pay” for vaccines.
• Few providers stocking adult vaccines, e.g. for fear of wastage 
[99].
• Low healthcare practitioner awareness and leadership, in part due 
to lack of training.
• Territorial limitations. In some settings, only some healthcare 
professions can vaccinate.
• Financial constraints and/or inconsistent reimbursement schemes
Improve vaccination 
infrastructure, as was done in 
Nigeria [100].
Obtain political commitment 
for vaccination. Implement fair 
reimbursement systems.
Establish vaccination advocates 
and champions.
Change in the focus of 
healthcare, in general, to reflect 
ageing populations.
Promote benefits to funders so 
no economic barriers to end-
user. Programs must be fully 
funded, to cover all doses in 
schedule.
Change workflows to 
incorporate adult vaccination; 
establish new infrastructure for 
accessing vaccines, including 
out-of-school.
Education and training of 
healthcare workers and 
encouragement to be fully 
vaccinated themselves; promote 
adult vaccination as a 
professional norm
Community perception In some settings, society places a lower value on the health of older people than 
that of children [101,102]
Promote change in societal 
values to recognize 
intergenerational connections
Notes. The list is modified from [79]. The focus on barriers and responses for adult vaccination was gathered from presentations and discussion at 
the meeting.
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Table 4
Gaps in knowledge supporting decision-making for adult and older adult immunization in developing 
countries.
Gap in Knowledge Comments
Burden of disease
What is the true burden of disease for infections that might be 
preventable in adults and older adults, especially in low- and 
middle-income countries (LMICs)?
Encourage gathering and sharing of data on broad measures of health (not 
just deaths due to disease); consider exacerbation of co-morbidities such as 
cardiovascular disease and chronic obstructive pulmonary disease
What are the broader impacts of vaccine-preventable diseases in 
older adults?
Large, long-term cohort studies are required to evaluate the impact of 
vaccine preventable diseases (and of vaccination) on frailty and relevant 
measures of quality of life, health care expenditure and wider social costs
Benefits of immunization for adults and older adults
Are there associations or causal links between infectious disease 
and non-communicable diseases (NCDs), and what is the impact 
of vaccination including in older adults?
NCD endpoints (including frailty) could be incorporated in vaccine trials, 
using measures appropriate for LMICs. Observational studies could also be 
informative
What are the broader economic benefits of vaccination in older 
adults?
As well as standard measures, there is a need to determine how to measure 
the economic value of adults at different ages, including in informal 
economy (e.g. as caregivers).
It is important to assess indirect economic value by preventing disease and 
disability, as well as by preventing exacerbation of existing co-morbidities. 
Patient and household surveys can help to identity the socioeconomic 
contribution of older adults
What data are available the impact of adult vaccines on anti-
microbial use in LMICs?
With sufficient baseline data, reduction in antibiotic use could be used as 
an endpoint in clinical studies of vaccines
Immune responses in adults and older adults
How does immune function change with ageing? Is the process 
of immunological ageing the same in HICs and LMICs?
Systems approaches could be applied to studying the biology of 
immunosenescence [103]
What are the impacts of obesity and other age-related or life-
style conditions (nutrition, social isolation, emotional distress, 
physical activity) on immune function?
Different populations in high-income countries (HICs) and LMICs and 
with different co-morbidities should be compared
To what extent do commonly used (adult) medications have an 
impact on immune responses to infection and vaccination?
As an example, the response to influenza vaccines in people taking statins 
is altered and may be lower [104,105]
Can we measure frailty, intrinsic capacity and environmental 
factors? Do we have the necessary tools and are they validated?
Observational and interventional studies with vaccines could examine the 
potential links between these factors and prevention of disease or decline?
Interrelationships between pediatric and adult vaccination 
programs
Should the need for and frequency of booster doses for infant 
vaccines during adulthood be revisited?
Examples include long-term immunogenicity and efficacy data for acellular 
pertussis [106] and tetanus vaccines
What is the potential impact of population (herd) immunity from 
vaccination of children on the need to vaccinate older adults?
In HICs, the value of infant/childhood conjugate vaccination 
(Pneumococcal conjugate vaccines, Haemophilus influenzae type b 
vaccines) has resulted in decreased disease burden in adults. More studies 
on population effects of seasonal influenza and pneumococcal vaccination 
of infants and young children are needed, especially in LMICs
What is the potential impact of pediatric varicella vaccination on 
herpes zoster in adults?
There have been suggestions that exposure to varicella may boost 
immunity to herpes zoster but the strength of this effect and its implications 
for vaccination are still being debated [107]
Program implementation
What are the major hurdles in communication to create 
awareness of the benefits of adult immunization?
Training of health care personnel and appropriate communication at all 
levels (policy makers, health care personnel, and patients/society will be 
required
What vaccine delivery platforms are best for achieving high 
coverage?
Reaching target vaccination groups outside the traditional infant 
vaccination requires new strategies, delivery locations, and effective 
communication to promote community demand
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